Navigation Links
Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone

RANCHO CORDOVA, Calif., March 2 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading developer and supplier of products that process and store adult stem cells, announced today that products derived from its Intellectual Property have been used to collect, process and store stem cells from cord blood in more than one million procedures since the products were introduced a decade ago. Cord blood stem cells have been used to reconstitute the blood cell forming marrow of patients undergoing treatment for leukemia and lymphoma. Cord blood is also being used in studies regarding treatment for more than 70 genetic diseases and most recently, cerebral palsy.

"The collection and processing of stem cells from cord blood utilizing these products has increased dramatically over the past decade, rising from 5,000 units in 1999 to more than 250,000 units in 2008," said Matthew Plavan, Chief Executive Officer of ThermoGenesis Corp.

These products include:

  • Sterile disposable bag sets used to collect cord blood from the placenta/umbilical cord and other manual disposable bag sets that concentrate the stem cells resident in the cord blood.
  • Novel sterile disposable bag sets that take advantage of the AutoXpress(TM) Platform to harvest and concentrate stem cells through automated means.

"We believe that the ongoing research regarding the therapeutic benefits of stem cells and the likely expansion of financial support for stem cell programs will mandate greater activity in the collection, processing, freezing and storage of cord blood stem cell units in the future," Plavan said.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

  • The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of automated devices that includes the AXP and the MarrowXpress and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow.
  • The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

                                ThermoGenesis Corp.
                        Web site:
                             Contact: Investor Relations
                                 +1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
2. ThermoGenesis Corp. Reports First Quarter 2008 Results
3. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
4. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
5. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
6. ThermoGenesis Reports First Quarter 2009 Results
7. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
8. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
9. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
10. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
11. Quantum light beams good for fast technology
Post Your Comments:
(Date:12/1/2015)... Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... coalition of obesity groups has filed a discrimination claim against the U.S. Department of ... coverage in their Affordable Care Act (ACA) plans are breaking the clause in the ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 2015 , ... Growth in medical payments per workers’ compensation claim in Louisiana ... and nonhospital care, according to a recent study by the Workers Compensation Research Institute ... found medical payments per claim with more than seven days of lost time continued ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Va. , Dec. 1, 2015  AccuTEC ... unveiled a new corporate logo and brand identity ... the design and engineering of bladed products where ... --> --> Serving manufacturers ... glass, and auto glass equipment, AccuTEC,s product lines ...
(Date:12/1/2015)... , Dec. 1, 2015 During the ... San Francisco, CA , Medinol ... the coronary marketplace. During a satellite symposium, "The ... Design to Minimize Restenosis", a renowned physician panel ... Medinol NIRxcell™ CoCr Coronary Stent System and the ...
(Date:12/1/2015)... ) has ... and Disposables Market by product, by Animal - ... offering. --> ) has announced ... Disposables Market by product, by Animal - Global ... --> Research and Markets ( ...
Breaking Medicine Technology: